Cell therapy weekly: Results of breakthrough trial for cell-based stroke therapy revealed
This week: An international marketing license for a mesenchymal stem cell (MSC)-based product for the prevention and treatment of graft-versus-host disease (GvHD), and a new technology that de-risks clinical trial and commercial shipments.
Please sign in or register for FREE
Sign in to RegMedNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Regenerative Medicine FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RegMedNet account also gives you access to communities on drug discovery, real-world evidence and 3D printing in medicine. Find out more>>